Grupo mixto en cáncer
Grupo mixto de investigación y traslación de cáncer de próstata
Coordinador/a del grupo
-
Miguel Unda Urzaiz
Coordinador de grupo
jesusmiguel.undaurzaiz@osakidetza.eus -
Arkaitz Carracedo Pérez
Coordinador de grupo
arkaitz.carracedoperez@osakidetza.eus
CV resumen
Publicaciones del grupo
Álvarez Ossorio JL, Rodrigo Aliaga M, Rodríguez Antolin A, Unda Urzaiz M, Calleja MÁ, de la Cruz Ruiz M, et al. Hormone sensitive protocol for metastatic prostate cancer, an update. Actas Urol Esp (Engl Ed). 2023; 47(4): 244-249. DOI: 10.1016/j.acuroe.2022.10.002.
Loizaga Iriarte A, Lacasa Viscasillas I, Rey Gonzalez S, Santos Martin A, Gonzalo Aparicio D, Ugalde Olano A, et al. Identifying prognostic parameters related to surgical technique in patients treated by robotic radical prostatectomy. Actas Urol Esp (Engl Ed). 2023; 47(1): 47-55. DOI: 10.1016/j.acuroe.2022.07.001.
Angulo JC, Álvarez-Ossorio JL, Domínguez-Escrig JL, Moyano JL, Sousa A, Fernández JM, et al. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. Eur Urol Oncol. 2023; 6(1): 58-66. DOI: 10.1016/j.euo.2022.10.008.
Martín-Saiz L, Abad-García B, Solano-Iturri JD, Mosteiro L, Martín-Allende J, Rueda Y, et al. Using the Synergy between HPLC-MS and MALDI-MS Imaging to Explore the Lipidomics of Clear Cell Renal Cell Carcinoma. Anal Chem. 2023; 95(4): 2285-2293. DOI: 10.1021/acs.analchem.2c03953.
Borque-Fernando A, Calleja-Hernández MA, Cózar-Olmo JM, Gómez-Iturriaga A, Pérez-Fentes DA, Puente-Vázquez J, et al. A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer. Actas Urol Esp (Engl Ed). 2023; 47(2): 111-126. DOI: 10.1016/j.acuroe.2022.12.004.
Borque-Fernando A, Calleja-Hernández MA, Cózar-Olmo JM, Gómez-Iturriaga A, Pérez-Fentes DA, Puente-Vázquez J, et al. Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors' reply. Actas Urol Esp (Engl Ed). 2023; 47(6): 392-393. DOI: 10.1016/j.acuroe.2023.04.014.
García-Vílchez R, Añazco-Guenkova AM, Dietmann S, López J, Morón-Calvente V, D'Ambrosi S, et al. METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer. Mol Cancer. 2023; 22(1): 119. DOI: 10.1186/s12943-023-01809-8.
Carracedo A. Metabolism in the tumor cell and beyond. Mol Oncol. 2023; 17(6): 921-924. DOI: 10.1002/1878-0261.13467.
Plou J, Valera PS, García I, Vila-Liarte D, Renero-Lecuna C, Ruiz-Cabello J, Carracedo A, Liz-Marzán LM. Machine Learning-Assisted High-Throughput SERS Classification of Cell Secretomes. Small. 2023 12:e2207658. DOI: 10.1002/smll.202207658.
Santasusagna S, Zhu S, Jawalagatti V, Carceles-Cordon M, Ertel A, Garcia-Longarte S, et al. Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer. Cancer Discov. 2023; 13(12): 2584-2609. DOI: 10.1158/2159-8290.CD-23-0306..
Tesis del grupo
Autor/a: Mikel Pujana Vaquerizo. Título: Molecular and biological consequences of targeting polyamine metabolism in prostate cancer. Directores/as: Arkaitz Carracedo Pérez, Amaia Zabala Letona. URL: http://hdl.handle.net/10810/61339.
Autor/a: Cristina Viera Bardón. Título: Metabolic control of prostate cancer aggressiveness by the tumor stroma. Directores/as: Arkaitz Carracedo Pérez, Janire Astobiza Pérez. URL: http://hdl.handle.net/10810/61590.
